Skip to content

Volatile organic compounds in exhaled breath for the detection of interstitial lung disease

VISION Study

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON28265
Enrollment
180
Registered
2020-11-02
Start date
2020-11-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial lung diseases

Interventions

None listed

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Eligible for participation in this study are all patients (= 18 years of age): - with a proven diagnosis of ILD (based on HRCT obtained in usual care) - at risk for ILD (based on medical history, chest X-ray, complaints or abnormal lung function obtained in usual care and for whom a HRCT is indicated) - without ILD (other diagnosis such as asthma or COPD; not necessarily HRCT indicated or performed)

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Recent (< 12 hours) intake of alcohol (checked by anamnesis of the study subject) - Unwillingness or inability to comply with the study protocol for any other reason In order to increase the applicability in clinical practice, there are no further restrictions.

Design outcomes

Primary

MeasureTime frame
Exhaled breath profiles obtained by sampling exhaled air using real time eNose technology to discriminate between patients with ILD, suspected for ILD (including post COVID-19 patients) and without ILD.

Secondary

MeasureTime frame
To identify diagnostic markers for early diagnosis and disease progression of ILD.

Contacts

Public ContactMiranda Geelhoed

LUMC

j.j.m.geelhoed@lumc.nl06-24274958

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)